Holen Sie sich die Stockscreener-App
5.72
2.39%
-0.14
Handel nachbörslich:
5.80
0.08
+1.40%
Schlusskurs vom Vortag:
$5.86
Offen:
$5.87
24-Stunden-Volumen:
632.44K
Relative Volume:
0.49
Marktkapitalisierung:
$794.60M
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.4592
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
+1.06%
1M Leistung:
+14.40%
6M Leistung:
+2.69%
1J Leistung:
-25.42%
1-Tages-Spanne:
$5.71
$5.87
1-Wochen-Bereich:
$5.61
$6.38
52-Wochen-Spanne:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Vergleichen Sie VIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.72 | 814.05M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Is now a turning point for Vir Biotechnology Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Will Vir Biotechnology Inc. stock deliver consistent dividends2025 Major Catalysts & Real-Time Stock Entry Alerts - newser.com
Is this a good reentry point in Vir Biotechnology Inc.Trade Ideas & Daily Stock Momentum Reports - newser.com
Why Vir Biotechnology Inc. stock remains on watchlistsEarnings Recap Summary & Growth Focused Investment Plans - newser.com
Endurance (Cayman) Ltd Svf Sells 466,242 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
What institutional flow reveals about Vir Biotechnology Inc.Stop Loss & Free Weekly Watchlist of Top Performers - newser.com
Study launches of VIR-5500 combined with ARPIs in mCRPC - urologytimes.com
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTE - PharmiWeb.com
Vir Biotechnology announces first patient dosed in part 3 of phase 1 trial - MarketScreener
Vir Biotechnology doses first patient in prostate cancer combo trial - Investing.com
Vir Biotechnology (VIR) Advances Prostate Cancer Treatment with VIR-5500 Trial - GuruFocus
Vir Biotechnology stock rises as company doses first patient in prostate cancer trial - Investing.com Canada
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer - Business Wire
Should You Allocate More Funds to DCX Systems Limited in YEARResistance Breakout Alerts & Accelerated Capital Growth - earlytimes.in
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? - Nasdaq
Vir Biotechnology (NASDAQ:VIR) Trading Up 9.7%Here's What Happened - MarketBeat
What analysts say about Vir Biotechnology Inc stockInsider Trading Compliance & Exceptional Return Opportunities - earlytimes.in
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025 - BioSpace
Vir Biotechnology to present hepatitis delta treatment results at liver meeting - Investing.com Canada
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $2,503,901.52 in Stock - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 73,955 Shares - MarketBeat
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liv - PharmiWeb.com
Vir Biotechnology to present hepatitis delta treatment results at liver meeting By Investing.com - Investing.com South Africa
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting - Business Wire
Using AI based signals to follow Vir Biotechnology Inc.Quarterly Trade Report & Verified Momentum Stock Alerts - newser.com
Price momentum metrics for Vir Biotechnology Inc. explainedWeekly Trade Analysis & Safe Entry Point Identification - newser.com
Is Vir Biotechnology Inc. a candidate for recovery playPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Clarius Group LLC Purchases 560,342 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
NKGen Biotech (NYSE:NKGN) versus AlloVir (NASDAQ:ALVR) Critical Analysis - Defense World
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
KaliVir Immunotherapeutics Announces Completion of First Intravenous Patient Cohort of STEALTH-001 S - PharmiWeb.com
Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025 - GlobeNewswire
Can machine learning forecast Vir Biotechnology Inc. recoveryWeekly Trend Recap & High Accuracy Swing Trade Signals - newser.com
Vir Biotechnology Shares Rise After Upgrade From BofA Securities - 富途牛牛
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gains Recap: Does Vir Biotechnology Inc stock benefit from AI growth2025 Short Interest & Entry and Exit Point Strategies - خودرو بانک
Earnings Recap: Does Vir Biotechnology Inc stock benefit from AI growth2025 Trade Ideas & High Return Trade Opportunity Guides - خودرو بانک
Goldman Sachs Group Inc. Boosts Holdings in Vir Biotechnology, Inc. $VIR - MarketBeat
Custom watchlist performance reports with Vir Biotechnology Inc.Weekly Trend Summary & AI Powered Market Trend Analysis - newser.com
Fed Meeting: Is Vir Biotechnology Inc stock a smart retirement pickWeekly Stock Recap & Proven Capital Preservation Tips - خودرو بانک
Retail Surge: Is ABRPRF stock risky to hold nowJuly 2025 Spike Watch & Fast Exit and Entry Strategy Plans - khodrobank.com
Vir Biotechnology's (VIR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Trading Down 4.7%Here's Why - MarketBeat
Technical Analysis: What are the analyst revisions for Vir Biotechnology Inc.Is LBTYB stock a good investment in YEARMarket Rally & Stepwise Entry and Exit Trade Signals - خودرو بانک
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vir Biotechnology Inc-Aktie (VIR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 07 '25 |
Sale |
5.60 |
72,133 |
404,154 |
16,087,611 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 03 '25 |
Sale |
5.56 |
450,342 |
2,501,785 |
16,233,699 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Oct 06 '25 |
Sale |
5.69 |
73,955 |
420,641 |
16,159,744 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):